綠城中國(03900.HK):已贖回5億美元高級永久資本證券
格隆匯12月29日丨綠城中國(03900.HK)公佈,有關公司的全資附屬公司耀麗控股有限公司發行於2021年可贖回的高級永久資本證券("2018證券"),本金總額為5億美元。2018證券並未於香港聯合交易所有限公司或任何其他證券交易所上市買賣。
其已於2021年12月28日將2018證券全額贖回。相應的,公司在本次贖回後並無已發行未償還的2018證券。
根據公司的統一資金安排計劃,公司贖回2018證券的資金來源包括但不限於(i)發行於2024年到期的本金總額為1.5億美元5.95%非上市高級票據的款項;以及(ii)融資協議下的借款款項等。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.